NCT01704378 - Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2001

Primary Completion Date

March 14, 2003

Study Completion Date

March 14, 2003

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart

Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal

Trial Locations (17)

2212

Novo Nordisk Investigational Site, Kongsvinger

2260

Novo Nordisk Investigational Site, Kirkenær

15850

Novo Nordisk Investigational Site, Lahti

48210

Novo Nordisk Investigational Site, Kotka

70210

Novo Nordisk Investigational Site, Kuopio

NO-2819

Novo Nordisk Investigational Site, Gjøvik

NO-3188

Novo Nordisk Investigational Site, Horten

NO-3675

Novo Nordisk Investigational Site, Notodden

791 82

Novo Nordisk Investigational Site, Falun

254 43

Novo Nordisk Investigational Site, Helsingborg

591 85

Novo Nordisk Investigational Site, Motala

DE7 1DY

Novo Nordisk Investigational Site, Derby

EH16 4SA

Novo Nordisk Investigational Site, Edinburgh

HU3 2JZ

Novo Nordisk Investigational Site, Hull

L7 8XP

Novo Nordisk Investigational Site, Liverpool

YO12 6QL

Novo Nordisk Investigational Site, Scarborough

CH63 4JY

Novo Nordisk Investigational Site, Wirral, Merseyside